Clinical Pharmacology Study of AK1830 (Drug-Drug Interaction Study in Healthy Men)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051200123

Enrollment

Registered

2021-01-29

Start date

2021-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

AK1830 oral administration and blood collection

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: The subjects will be individuals who meet all of the following criteria. [1] Healthy men [2] Individuals >=20 to <45 years of age at the time of informed consent [3] Individuals who fully understand the details of the study and who are capable of providing written informed consent

Exclusion criteria

Exclusion criteria: Individuals meeting any of the following criteria will be excluded from the study. [1] Past history of disease of kidney, liver, heart, brain, or other conditions considered unsuitable for this study [2] Past history of disease or surgery that could affect absorption of the investigational product or designated concomitant drug [3]Other protocol defined exclusion criteria could apply

Design outcomes

Primary

Measure	Time frame
Plasma concentration of compound(s)	—

Contacts

Public ContactClinical Trial Information Contact for

ASAHI KASEI THERAPEUTICS CORPORATION

ct-info@om.asahi-kasei.co.jp+81-3-6699-3600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026